Arax Advisory Partners
KYTX icon

Arax Advisory Partners’s Kyverna Therapeutics KYTX Stock Holding History

Arax Advisory Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98 Hold
11
– – ﹤0.01% 5140
2026
Q1 		$95 Hold
11
– – ﹤0.01% 3619
2025
Q4 		$103 Hold
11
– – ﹤0.01% 3822
2025
Q3 		$66 Buy
+11
New +$44 ﹤0.01% 3525

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Arax Advisory Partners's KYTX Position: Q2 2026 in Review

Arax Advisory Partners held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 11 shares worth $98. The position accounts for ﹤0.01% of the portfolio, ranked #5140.

Arax Advisory Partners first reported a position in KYTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $103 in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Arax Advisory Partners held 11 shares of Kyverna Therapeutics worth $98 as of Q2 2026.
  • Arax Advisory Partners left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5140 holding.
  • Arax Advisory Partners first reported a position in Kyverna Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Kyverna Therapeutics position peaked at $103 in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.